MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Abeona Therapeutics Inc

Suletud

4.46 -5.71

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.42

Max

4.72

Põhinäitajad

By Trading Economics

Töötajad

136

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+292.23% upside

Turustatistika

By TradingEconomics

Turukapital

4.4M

218M

Eelmine avamishind

10.17

Eelmine sulgemishind

4.46

Abeona Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2024, 23:00 UTC

Suurimad hinnamuutused turgudel

Abeona Therapeutics Shares Down 53% After FDA Complete Response Letter

Võrdlus sarnastega

Hinnamuutus

Abeona Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

292.23% tõus

12 kuu keskmine prognoos

Keskmine 18.67 USD  292.23%

Kõrge 25 USD

Madal 15 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Abeona Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

3

Osta

0

Hoia

0

Müü

Finantsandmed

$

Ettevõttest Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.